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Neuropathic pain is common (7-10%), and has a high impact on individuals and society.  Health-related 
quality of life was rated as “worse than death” by 17% of people reporting neuropathic pain.  In this 
review we describe challenges associated with assessing neuropathic pain, particularly in primary care 
and population-based research.  We provide an updated review of clinical, socio-demographic, 
psychological and genetic factors associated with its presence, severity and response to treatment, 
based on recent epidemiological and related research.  This information adds to our understanding of 
the biological mechanisms of neuropathic pain clinical practice, as well as approaches to treatment and 
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Neuropathic pain is common (7-10%), and has a high impact on individuals and society.  Health-
related quality of life was rated as “worse than death” by 17% of people reporting neuropathic pain.  
In this review we describe challenges associated with assessing neuropathic pain, particularly in 
primary care and population-based research.  We provide an updated review of clinical, socio-
demographic, psychological and genetic factors associated with its presence, severity and response 
to treatment, based on recent epidemiological and related research.  This information adds to our 
understanding of the biological mechanisms of neuropathic pain clinical practice, as well as 
approaches to treatment and prevention.  We consider some of the ways in which this will also 




Neuropathic pain arises as a direct consequence of a lesion or disease affecting the somatosensory 
system.[87]  It can be peripheral in origin, as a result of nerve injury or disease (e.g. lumbar 
radiculopathy, postherpetic neuralgia, diabetic or HIV-related neuropathy, or postsurgical pain), or 
central (e.g. post-stroke or spinal cord injury).  It is characterized by unpleasant symptoms, such as 
shooting or burning pain, numbness, allodynia, and other sensations that are very difficult to 
describe.  Clinically, particularly in primary care (where time for assessment is limited), it is 
important to identify (possible) neuropathic pain, distinguishing it from other pain types (including 
nociceptive pain), as it generally fails to respond to standard analgesics (e.g. non-steroidal anti-
inflammatories) but requires a different analgesic approach.[25]  As all analgesics potentially cause 
harm as well as benefit, the distinction will promote safe and effective prescribing. 
 
However, “definite” neuropathic pain can relatively rarely be confirmed, particularly in non-
specialist settings.  According to the widely accepted grading system proposed by the International 
Association for the Study of Pain (IASP)’s Special Interest Group on Neuropathic Pain (NeuPSIG), this 
diagnosis requires: (1) a history of a relevant neurological lesion or disease, and pain in a 
neuroanatomically plausible distribution; (2) sensory signs in the same distribution; and (3) a 
diagnostic test confirming the lesion or disease in the somatosensory system.[26]  Diagnostic tests 
might include imaging (e.g. MRI to demonstrate nerve lesion), intra-epidermal nerve fibre density 
measurement on skin biopsy, neurophysiological testing (e.g. nerve conduction studies), or genetic 
testing to demonstrate a relevant hereditary disorder (e.g. erythromelalgia).  Note that the term 
“definite” in this grading system is itself relative, and the above tests do not always confirm 
causality. 
 
Much therefore depends on the sharing of a clear history and the elicitation of positive or negative 
sensory signs.  Again, though, in primary care settings, time and experience limit the possibility of 
detailed clinical examination and it is therefore the history that assumes dominance in the 
assessment of pain.[31,32]  This can determine the presence of “possible” neuropathic pain,[26] and 
allow treatment to begin according to an evidence-based neuropathic pain prescribing pathway.[74]  
Moreover, there is recent and increasing recognition that some classically “non-neuropathic” painful 
conditions can give rise to symptoms more commonly associated with neuropathic pain, and some 


































































antidepressants and gabapentinoids.[84]  For example, a systematic review found that pain was 
neuropathic in character in 23% of people with knee or hip osteoarthritis,[27] and this was found to 
be >6 times more likely in those who had experienced knee surgery.[89]  Similarly, a Finnish study 
found that 34% of people with fibromyalgia had clinically verified neuropathic pain.[29]  Systematic 
reviews have found that 18.7%-27.6% of people with cancer pain have pain with a neuropathic 
mechanism. [7,69] 
 
Not everyone who experiences a lesion or disease of the somatosensory system goes on to develop 
neuropathic pain.  For example only around 26% of those with type 2 diabetes and 21% of those 
who experience herpes zoster infection develop neuropathic pain.[34]  While the mechanisms and 
associated risk factors for some of this variation are becoming understood,[14] much remains 
unexplained, and yet would inform prevention and mitigation.  There is therefore an important role 
for epidemiology in our understanding of neuropathic pain. 
 
Epidemiology is, “The study of the occurrence and distribution of health-related states or events in 
specified populations, including the study of the determinants influencing such states, and the 
application of this knowledge to control the health problems.”[66]  Good information on the 
prevalence helps to determine the resources required to address the problem, while knowledge of 
risk helps with diagnosis and prevention, as well as the identification of possible treatment 
strategies.  At the population level, to inform primary care (where most neuropathic pain presents 
and is managed), this requires community-based studies, with large sample sizes.  Just as non-
specialist assessment of possible neuropathic pain relies primarily on a clinical history, so too must 
population studies rely on efficient reports of symptoms, as clinical examination is generally not 
feasible in large studies.  This review updates our understanding of the prevalence of neuropathic 
pain in the community, and genetic and non-genetic factors associated with its presence, severity, 
and response to treatment, mainly from population studies. 
 




Estimating population prevalence with sufficient precision requires a large sample size.  For example, 
for 95% confidence to identify a prevalence of 10% requires a sample size of ~3,500 to achieve a 
precision of ±1%.[22]  Initial estimates of the prevalence of neuropathic pain, based on the known 
prevalence of underlying conditions, were approximately 1-2%.[12]  Subsequently, simple 
questionnaires were developed and validated to determine the presence of neuropathic 
characteristics in any pain.  These included the S-LANSS, the DN4, and PainDETECT, each with many 
similarities, though a few differences.[6]  Based on the first two of these, general population studies 
with responding sample sizes of 3,002 and 23,712 found prevalences of 8% and 6.9% in the UK and 
France respectively.[10,86]  Importantly, the cases identified were described as having “pain of 
predominantly neuropathic origin” or “pain with neuropathic characteristics”, rather than 
“neuropathic pain”.   Based on the above IASP grading system, they could not even be described as 
“possible neuropathic pain” as there was no successful attempt systematically to determine an 
underlying lesion or disease, nor of neuroanatomically plausible distribution of pain.  No subsequent 


































































these diagnostic factors.  Some, such as an early study using PainDETECT (which found that 37% of 
people presenting to primary care with low back pain were also categorised with lumbar 
radiculopathy)[28] have been able to approach this in individual conditions.  A systematic review of 
population-based prevalence studies considered the true prevalence of pain with neuropathic 
characteristics to be 7-10%.[34]  The proportion of positive responses to the S-LANSS, DN4 and Pain 
DETECT screening instruments may be higher than the true population prevalence, for reasons 
including response bias and imperfect sensitivity and specificity.[70]  Although these estimates may 
therefore be inflated, this means that up to 10% of people presenting in primary care should 
potentially embark upon an anti-neuropathic treatment pathway.  It also means that around 90% 





Neuropathic pain has a high impact as well as prevalence.  Compared with non-neuropathic pain, 
neuropathic pain is likely to be rated as more severe.[78]  All measured dimensions of health and 
quality of life (QoL) are rated worse in neuropathic pain than in non-neuropathic pain,[21] [49] [79] 
and this remains true even when pain is adjusted for its severity.[78]  Using the EQ5D questionnaire 
to measure QoL, a population study found that 17% of people with pain of neuropathic 
characteristics produced a score less than zero, meaning that they rated QoL as “worse than 
death”,[85] though comparison of scores between different QoL measures makes it difficult to 
interpret such a rating precisely[73].  The reasons for this high impact are multi-dimensional, and 
include the complexity, severity and unpleasantness of symptoms, and the burden and side effects 
of treatment (and their frequently poor outcomes).[15]  This highlights the severity of the condition, 
and the need to understand its prevention and management. 
 
2.3 Risk factors: non-genetic 
We previously reviewed non-genetic risk factors for neuropathic pain, and these included older age, 
female gender, manual occupation and social deprivation, as well as various clinical and 
psychological factors.[77]  When assessing more recent literature with respect to non-genetic 
factors and neuropathic pain (using relevant key terms in a non-systematic approach from 2008 
onwards; Table 1), there are a number of observations that can be made. First, with respect to study 
design, the great majority of studies are cross-sectional and only a few are longitudinal [9,53,82].  
This means that we are unable to determine any causal relationship in many of the associations that 
have been reported, and a bidirectional relationship is often plausible.  Secondly, most studies do 
not conform to the above criteria for defining neuropathic pain,[26] so there is heterogeneity in 
reported associations and effect sizes.  Thirdly, differences in the statistical methods make the 
results difficult to compare directly.  Fourthly, there is not always a clear description of the size or 
definition of any “control” group.  Nevertheless some potential risk factors are apparent. 
 
2.3.1 Demographic risk factors 
Demographic factors are generally non-modifiable but can inform awareness of risk in particular 
sections of the population.  For example, as with chronic pain generally, older age has been 


































































particular, older age has been identified in studies of painful diabetic neuropathy,[2] [43] post 
herpetic neuralgia[9] [64] and neuropathic pain in myocardial infarction.[100]  Likewise gender is 
consistently associated with neuropathic pain, potentially alluding to differing underlying biological 
and/or psychological mechanisms.  The majority of studies report a higher prevalence of 
neuropathic pain and higher pain intensity amongst female participants,[64] mainly in painful 
diabetic neuropathy.[1] [3] [4] [43]  However, a French study conducted in patients with herpes 
zoster found that male gender was an independent predictor of persistent post-herpetic 
neuralgia.[9]    
 
There is limited evidence that ethnicity is an independent risk factor for neuropathic pain.  A recent 
study conducted in the USA found that prevalence rates of neuropathic pain (as assessed by the 
PainDETECT across a range of aetiologies) in people with pain was higher in Hispanic and non-
Hispanic black males and females, compared to white males and females, across all age groups 
analysed.[19]  Furthermore, military personnel of African descent were found to be more 
susceptible to neuropathic pain resulting from non-freezing cold injury than their non-African 
counterparts.[90]  One study conducted in the Middle-East region found that living in Egypt was a 
risk factor for neuropathic pain (compared to living in Kuwait/UAE and Lebanon), but did not 
specifically analyse ethnic origin.[43]  However most published studies recruited from a 
geographically limited population and/or did not report ethnic diversity.  They are also generally 
limited by inadequate consideration of potential confounders that include socio-economic status, 
cultural factors, and access to care. 
 
2.3.2 Psychological risk factors 
The relationship between neuropathic pain and psychological factors is complicated, with the 
presence of comorbidities such as depression, anxiety and sleep disorders suggesting shared 
biological and genetic pathways.[14]  This area has yet to be fully explored, particularly with respect 
to the underlying genetics, and since there could feasibly be a reciprocal interaction in terms of the 
temporal relationship, longitudinal studies are particularly important for these factors.  For example, 
in a longitudinal study of patients with post-total joint replacement neuropathic pain, a bidirectional 
relationship with sleep disturbance was demonstrated.[82]  Another longitudinal study in the USA 
found an association between increasing depressive symptoms and neuropathic pain in people with 
HIV-sensory neuropathy (HIV-SN).[1] 
 
Recent cross-sectional studies generally support previous findings of associations between adverse 
psychological health and neuropathic pain.  For example poor overall mental health status was 
associated with neuropathic pain in patients with rheumatoid arthritis,[49] and anxiety, pain 
catastrophizing and fatigue were associated with the phenotypically similar neuropathic-like knee 
pain.[23]   
 
2.3.3 Social/lifestyle risk factors 
Neuropathic pain is associated with a number of behavioural and social factors, some of which are 
sufficiently modifiable to make them important targets for preventative measures.  These factors 
are important as they are those most amenable to modification by the patients themselves.  This is 
illustrated by alcohol and smoking, which are both associated with neuropathic pain.[11] [64]  While 


































































to establish the temporal relationship with alcohol (whose consumption might increase after the 
onset of neuropathic pain).  Increased physical activity has been found to confer a protective effect 
against neuropathic pain in patients with comorbid diabetes and myocardial infarction.[100]  
 
Body mass index (BMI)/weight and waist circumference have been found to be associated with 
neuropathic pain in diabetic populations.[2] [43] [80] [99]  Obesity can also place joints under strain, 
and limit physical activity, which are potential explanations for its association with neuropathic pain 
found in rheumatoid arthritis.[42]   
 
Finally, poor health-related QoL also appears to be predictive of neuropathic pain,[3] as well as an 
outcome (as noted above).    
          
2.3.4 Clinical risk and biomarkers for neuropathic pain 
In diabetes, a longer disease duration has been associated with painful diabetic neuropathy[2] [43] 
and there have been associations found with diabetes type,[43] [79] though these are contradictory 
between type 1 and type 2 diabetes.  The association of nephropathy with neuropathic pain is likely 
to be a result of both arising as complications of diabetes.[2] [11]  The same is probably true of 
peripheral arterial disease, which has been found to be associated with neuropathic pain in two 
studies and arises as a complication of diabetes.[99,100]  Similarly, biomarkers such as low HDL and 
high triglycerides are all associated with diabetes as well as with neuropathic pain[2] and further 
longitudinal analysis is required to establish their apparent role in neuropathic pain.   
 
Away from diabetes, detectable plasma viral load at study entry, current or past combination 
antiretroviral therapy (CART), and history of opioid abuse predict neuropathic pain in patients with 
HIV-SN.[53]  The association of CART is thought to reflect the more advanced nature of HIV disease, 
compared to those who were CART-naïve.  Pain itself appears to predict neuropathic pain, with 
multiple regional pains found to be associated with neuropathic-like knee pain (NKP),[23] and high 
pain intensity and interference associated with the development of post herpetic neuralgia.[11] 
Given that neuropathic and nociceptive pain can both be present at the same time, it is interesting 
to note that the association with multiple pain regions comes from a multinomial regression analysis 
that includes a heterogeneous group of participants with “possible” NKP, as well as those with 
“definite” and “no” NKP (as defined by the PainDETECT).  Additionally, the extent of hyperalgesia 
around a surgical incision 48 hours after bone surgery was associated with subsequent chronic post-
surgical neuropathic pain.[55]  
 
2.4 Risk factors: genetic  
 
There is evidence from a recent twins study that neuropathic pain encompasses a substantial 
heritable component (37%), indicating that genetic factors are likely to contribute to the inter-
individual variability.[58] Attention has therefore turned to identifying genetic factors associated 
with neuropathic pain.  These can help elucidate the underlying biological mechanisms, and 
therefore potential treatment targets, as well as improving assessment of risk.  Challenges such as 
sample size requirements and the need for consistent approaches to phenotyping have limited most 



































































Specific genes have been associated with rare monogenic disorders, including congenital sensitivity 
to pain with anhidrosis, paroxysmal extreme pain disorders and erythromelalgia which are caused by 
gain-of-function or loss-of-function mutations in a voltage-gated sodium channel gene 
(SCN9A).[18,24,97]   Individuals affected with hereditary neuropathy and debilitating neuropathic 
pain have been reported to carry Trp101 stop mutations in Myelin protein zero (MPZ).[67]  
However, any genetic predisposition to the presence, severity or progression of common 
neuropathic pain conditions, or their response to treatment, probably results from multiple genes.  
A recent systematic review highlighted the success and limitations of the 29 published genetic 
association studies examining the risk of developing neuropathic pain up to 2017.[91]  Most of the 
studies had applied a candidate gene approach, and they identified susceptibility genes that are 
mainly involved in the following functions: neurotransmission or ion channels (catechol-O-
methyltransferase (COMT), opioid receptor Mu 1 (OPRM1), GTP cyclohydrase (GCH1),  SCN9A, 
voltage-dependent calcium channel gamma subunit 2 (CACNG2), solute carrier family 6 member 4 
protein (SLC6A4)); immune responses (human leukocyte genes (HLA-A, -B, -DRB1and -DQB1), 
tumour necrosis factor alpha (TNFA), interleukin-6 (IL6), IL10, and IL1R2)); and iron metabolism 
(aconitase 1 (ACO1), beta-2-microglobulin (B2M), bone morphogenetic protein 6 (BMP6), transferrin 
(TF), ceruloplasmin (CP), transferrin receptor (TFRC), frataxin (FXN) and solute carrier family 11 
member 2 (SLC11A2)) (Figure 1).   
 
2.4.1 Candidate gene studies 
The most frequently investigated gene was COMT (five studies) but this was not significantly 
associated in meta-analysis.[91]  However, a recent study (n=590) reported that a COMT variant 
confers an increased risk of distal neuropathic pain in HIV-SN patients of European and African 
ancestry.[96]  Moreover, COMT variants were also associated with pain intensity in patients who 
underwent lumbar discectomy.[71]  Similarly, studies have reported the association of OPRM1 
variants with neuropathic pain susceptibility inconsistently in different populations. This may be due 
to heterogeneous case-control criteria and small sample sizes.[91]  One study found an association 
between OPRM1 variants and pain intensity in post-operative patients.[63]  HLA genes were 
consistently replicated in association with persistent neuropathic pain after shingles[72,83] or 
surgery.[20]  GCH1 variants were found to be associated with neuropathic pain susceptibility in post-
surgery patients [36] and pain sensitivity in patients with HIV-SN.[38] Cytokine gene (IL6) harbouring 
variants were reported to be associated with sciatica [62] but not with post-surgical pain in patients 
who had undergone breast cancer surgery[81]. The latter study also found associations between 
polymorphisms in the cytokine genes (IL10 and IL1R2) and post-surgical pain[81]. Separately, TNF 
polymorphisms or haplotypes have shown significant association with neuropathic pain 
susceptibility in post-operative patients [46] and pain intensity in Black Southern Africans With HIV-
SN.[39] Several genetic polymorphisms in iron-metabolism genes (ACO1, B2M, CP, FXN, TF, TFRC, 
BMP6 and SLC11A2)[45] and a variant in an ion channel gene (CACNG2)[61] have been investigated 
by single studies, but not yet been replicated.  Notably, the best known sodium ion channel gene 
associated with rare neuropathic pain conditions (SCN9A) has also been shown to be associated with 
the presence and severity of neuropathic pain in diabetes.[51].  However, a recent study reported no 
association between either a specific variant in SCN9A, or a variant in nerve growth factor gene, 


































































mutations in SCN11A have also been found in patients with painful peripheral neuropathy[40], and a 
recent study identified a pathological mutation in SCN10A in diabetic patients with painful 
neuropathy.[33]  A genetic variant in potassium channel alpha subunit (KCNS1) gene was associated 
with the presence of neuropathic pain caused by multiple aetiologies [17], and in a separate study 
KCNS1 haplotypes were associated with pain intensity in patients with HIV-SN.[38]  Purinergic 
receptor 7 (P2RX7) harbouring variants were associated with pain sensitivity in diabetic patients with 
neuropathic pain.[88]  Almost all of these studies had relatively small sample sizes and varying 
phenotyping. Thus, specific causative variants for NeuP have yet to be definitively identified.   
 
2.4.2 Genome-wide association studies 
Genome-wide association studies (GWAS), with hypothesis-free scanning of the whole genome, can 
provide novel biological insights into common and complex traits.  There have been five GWAS 
focusing on neuropathic pain susceptibility published to date, examining populations with diabetic 
neuropathic pain, post-surgical pain or sciatica and cancer-related neuropathic pain, all in patients of 
European ancestry.  These each used different phenotyping methods including electronic dispensed 
medication records, the PainDETECT questionnaire, self-administered questionnaires and physician 
diagnosis based on symptoms.  Two, using medication records alone (one with additional recorded 
neuropathy assessment), were performed in a diabetic population and found novel suggestive 
variants near glial cell line-derived neurotrophic factor family receptor alpha 2 (GFRA2), high 
mobility group box 1 (HMGB1P46) and zinc finger and SCAN domain containing 20 (ZSCAN20), but 
these have not yet been replicated in an independent study.[56,57]  A meta-analysis of GWAS of 
neuropathic pain in post-surgical pain patients found a new suggestive variant near the protein 
kinase c alpha (PRKCA) gene which is involved in receptor signalling and apoptosis signalling.[93]  A 
large-scale meta-analysis of GWAS in sciatica found two novel genome-wide significant loci near 
nuclear factor I B-type (NFIB) and myosin superfamily 5 A (MYO5A) in the discovery study and 
replicated the locus near NFIB in an independent Finnish population.[50]  A recent GWAS of 
neuropathic pain in head and neck cancer patients with neuropathy found four novel genome-wide 
significant loci near the sortin nexin (SNX8), purkinje cell protein 2 (PCP2), Kininogen-l (KNG1) and 
RAR-related orphan receptor alpha (RORA) genes.[68]  These findings still require replication, and 
their potential biological roles in neuropathic pain are unclear.  Separately, a recent GWAS identified 
16 susceptibility loci for carpal tunnel syndrome (which often includes neuropathic pain); these were 
mostly associated with growth and structural processes.[95] 
 
2.5 Factors associated with response to treatment 
In comparison to the presence and onset of neuropathic pain, there are relatively few 
epidemiological studies analysing response to treatment.   
 
2.5.1 Non-genetic factors 
The few studies that have been conducted in treatment response have tended to be exploratory 
post-hoc analyses of pre-existing clinical trials focussing on a specific set of drugs (either 
antidepressants or anticonvulsants) in patients with diabetes,[54] [75] [98] [101] although one study 


































































Of the recommended first-line medications for neuropathic pain, duloxetine and pregabalin have 
been the most studied in this context.  Higher baseline pain intensity was associated with better 
responses to duloxetine in patients with diabetic peripheral neuropathic pain,[55] whilst severe 
sleep disturbance was associated with better responses to pregabalin.[92]  A further study found 
that pain reduction in response to duloxetine was greater in the subset of patients with no mood 
symptoms, which is an interesting finding considering duloxetine is an antidepressant.[54]  
Conversely, better responses were found in patients with depression who were treated with 
duloxetine rather than gabapentinoids.[101]  Finally, a study of three antidepressants (imipramine, 
venlafaxine and escitalopram) and two anticonvulsants (pregabalin and oxcarbazepine) in painful 
polyneuropathy found that people with diabetes had better response to the anticonvulsants (mainly 
driven by oxcarbazepine) than people without diabetes, and people with a shorter duration of 
neuropathic pain had a better response to the antidepressants.[75]    
 
2.5.2 Genetic factors 
A candidate gene association study examined the association of variants in the serotonin receptor 
2C (HTR2C), serotonin receptor 2A (HTR2A), ATP Binding Cassette Subfamily B Member 1 (ABCB1), 
cytochrome (CYP2C19) and serotonin transporter (SLC6A4) genes with treatment response to 
escitalopram in neuropathic pain. Of these, a significant association was only found with one variant 
in HTR2C, with which carriers of the C allele experienced better pain relief than carriers of the G 
allele.[13]  Another study tested the association of an OPRM1 variant with response to treatment 
among 96 patients oxaliplatin-induced painful neuropathy.  This found that the patients who carried 
the homozygous genotype (AA) of OPRM1 A118G had a better response to tramadol and 
acetaminophen combination treatment than other carriers.[52]  A recent study investigated the 
association of COMT, OPRM1, ABCB1, CYP2C19 and CYP2D6 variants with the response to treatment 
of neuropathic pain with nortriptyline and morphine in 25 Caucasian patients.  Among 34 variants in 
these genes, they discovered a significant association (p=4.89×10-5) between the carriers of C allele 
of rs1045642 in ABCB1 and pain relief from combination therapy (nortriptyline and morphine) after 
Bonferroni correction for multiple testing, but no significant association with treatment response to 
either nortriptyline or morphine alone. They replicated this association in thirty-seven patients who 
were taking amitriptyline or nortriptyline along with morphine or fentanyl from the UK Biobank 
cohort (p=0.02).[5]  Pharmacogenomics research in neuropathic pain are still at an early stage and 
this finding, like others, warrants replication in a large-scale cohort of patients with neuropathic 
pain. GWAS using large cohorts are also needed to uncover genetic variants associated with 




Available medical, interventional and psychological therapies for neuropathic pain have been 
recently reviewed by Colloca et al,[15] among others.  Among the first line medical treatments 
recommended for neuropathic pain are the gabapentinoids – gabapentin and pregabalin.[25,74] [60]  
Acting as α2δ ligands at voltage-dependent calcium channels, these inhibit neuropathic pain signals 
and were found to have numbers-needed-to-treat (NNTs) of 7.9 and 7.2 respectively, in order to 
achieve significant pain relief.[25]  This was sufficient for IASP to make a recommendation to the 


































































Medicines, to encourage their availability in every country.[47][94] Many of the countries which did 
not include a gabapentinoid in their National Essential Medicines List were likely to have a high 
prevalence of conditions associated with neuropathic pain (e.g. diabetes, HIV),[48] and it was 
estimated that >59 million people would achieve >50% reduction in neuropathic pain severity if 
gabapentin were available worldwide.[47]  The recommendation was rejected by the WHO, though 
discussions are continuing. 
 
One of the reasons for rejection was the growing recognition of harms associated with 
gabapentinoids.[76] [41]  These include misuse, addiction and overdose, side effects including 
dizziness, drowsiness and fatigue, and added dangers when co-prescribed with opioids.[30]  Indeed, 
population studies in the US, UK and elsewhere have found the prescribing rates of gabapentinoids 
to be rising rapidly and steadily, mirroring those previously found with opioids.[59] [44]   
 
Gabapentinoids were recommended as first-line treatment of neuropathic pain by NeuPSIG in their 
detailed systematic review.[25]  Alternative recommended first-line treatments, in the absence of 
gabapentinoids, are tri-cyclic antidepressants (TCAs, e.g. amitriptyline) and serotonin-noradrenaline 
reuptake inhibitors (SNRIs, e.g. duloxetine).  TCAs were found to be on the Essential Medicines list of 




In summary, neuropathic pain continues to present a high prevalence and impact around the world, 
and we need approaches to its prevention and management that are applicable in the community, 
to reduce the global burden.[8]  Epidemiological studies have highlighted the population distribution 
of neuropathic pain, and socio-demographic, psychological, and clinical factors which can inform 
targeted approaches.  Many of these factors are similar to those associated with other chronic 
conditions, and require population-based public health and political management for their 
successful translation.  Potentially, epidemiological studies can also inform the prognosis of 
neuropathic pain, including its natural course and factors associated with different outcomes.[37]  
This is of concern to patients and may inform treatment decisions, but requires longitudinal cohort 
studies, of which there have been few in neuropathic pain to date.[34] 
 
Although genetic studies have shed some light on the aetiology of neuropathic pain, they generally 
lack (successful) replication attempts and explain only a small amount of the genetic risk.[91]  Large-
scale GWAS and replication in studies with consistent phenotyping are required, in combination with 
detailed analysis of their interaction with non-genetic factors and this will require collaborative 
population-based approaches to generate adequate sample sizes.  One such study is underway and 
will report soon: DOLORisk (http://dolorisk.eu/),[65] a European consortium funded by EU Horizon 
2020.  DOLORisk includes an 18-month population follow-up study whose analysis will identify 
factors associated with exacerbation and resolution, thus informing prognosis.  Meanwhile, the UK 
Biobank (n=500,000) has recently undertaken a re-phenotyping exercise which includes assessment 
of neuropathic pain using the DN4.  The survey is still being completed, but an expected response of 
~175,000 participants could generate 12,000 with neuropathic pain, [34] providing the largest 



































































Although effective medical treatments are available for neuropathic pain, we need to be wary of the 
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Figure 1.  Summary of genetic and non-genetic factors shown to be associated with the presence and/or severity of neuropathic pain 
 



































































Table 1.  List of studies identifying factors associated with neuropathic pain onset/presence and their characteristics  
 
Study Design Population Aetiology NeuP 
Assessment 
Cases/Controls Analysis Significant 
Factors 
Odds Ratio (95% CI) 








2. NeuP in 
diabetes 
MNSI > 2 and 
positive response 






1. Age (years) 
Weight (kg) 
Diabetes  
PAD (ABI < 
0.9) 
2. Age (years) 
Weight (kg)* 














Van Acker et al., 2009 
[2] 
Cross-Sectional Belgium DPN with NeuP A positive 
Neuropen® test 




Age (per 10 years) 
Diabetes Duration 
(per 5 years) 
Obesity 






























MNSI > 2 and 
positive response 



















PAD (ABI < 
0.9) 













Parruti et al., 2010 
[64] 
Longitudinal Italy PHN Pain in the 
































































































Spallone et al., 2011 
[80] 


























NeuP (reported as 
pDPN) 
DN4 ≥ 4 ?* Stepwise 
multivariate 




  50-64 years 
  ≥65 years 





  Kuwait/UAE 













Abbott et al., 2011 [1] Cross-Sectional UK (North-west 
England) 










Bouhassira et al., 
2012 [9] 
Longitudinal France PHN GP confirmed 
zoster-related 
pain (pain in the 
same area as the 
zoster rash) at 
least 3 months 




binary regression  
Gender (males) 
Age (≥70 years) 












Martinez et al., 2012 
[55] 
Cross-Sectional France CPSNP (following 
ICBH) 
DN4 ≥ 4 19/63 Multivariate 
binary regression 
Area of secondary 
hyperalgesia 









































































DN4 score at 48h 
post-surgery 
1.75 (1.10-2.60) 
Bouhassira et al., 
2013 [11] 
Cross-Sectional France Diabetes with 
NeuP 
DN4 ≥ 3 (in 
patients with pain 
















Malvar et al., 2015 
[53] 










Plasma VL at study 
entry (detectable) 
CART use at study 
entry  







  BDI-II 14-19 
  BDI-II 20-28 
































BMI ≥ 22 
3.87 (1.76-8.51) 
2.48 (1.13-5.17) 
Stocks et al., 2018 
[82] 
Longitudinal UK (Nottingham) Post-TJR (knee or 
hip) with NeuP 
PainDETECT ≥ 13 ?* Cox regression 
model 
Sleep disturbance 
(MOS-SS ≤ 60) 
2.75 (1.21-6.26)c 
Fernandes et al., 2018 
[23] 
Cross-Sectional UK (East Midlands) KP with NeuP 
(reported as NKP) 
Modified 
PainDETECT 
  13-18 = Possible 
NKP   
  ≥ 19 = Definite 
NKP  
Definite = 366 
Possible = 462 








































































































Solaro et al., 2018 
[79] 
Cross-Sectional Italy MS with NeuP 
(distinguished as 
TN, LP, ON or 
ongoing NeuP) 
Exclusion of other 
likely causes of 
pain, pain with a 
plausible 
neuroanatomical 
distribution, DN4  









Disability (EDSS)  1.33 (1.18-1.49) 
Alkhatatbeh et al., 
2019 [3] 
Cross-Sectional Jordan T2D with NeuP PainDETECT 
  0-12 = NociP 
  13-18 = Unclear 
  ≥ 19 = NeuP 
NeuP = 64 
Unclear = 58 
NociP = 117 
Multivariate 
ordinal regression  
Gender (Female) 2.45 (1.29-4.67) 
Barbosa et al., 2019 
[4] 




DN4 ≥ 4 and 
LANSS ≥ 12 (in 
participants with 
MNSI ≥ 6) 
Painful DSPN = 67 
painless DSPN = 
85 
no pain, no DSPN 














ABI, ankle brachial index; AIC, Akaike information criterion; BDI-II, Beck Depression Inventory – second edition; BMI, body mass index; CART, combination 
antiretroviral therapy; CI, confidence interval; CPSNP, chronic postsurgical neuropathic pain; CR, clinical remission; DAS28-ER, disease activity score-28 based on 
erythrocyte sedimentation rate; DN4, Douleur Neuropathique en 4 Questions; DPN, diabetic peripheral neuropathy; DSPN, distal symmetrical polyneuropathy; 
EDSS, Expanded Disability Status Scale; GP, general practitioner;  HADS, Hospital and Anxiety Depression Scale; HbA1c, glycated haemoglobin; HDL, high-density 
lipoprotein; HIV-SN, human immunodeficiency virus-sensory neuropathy; HZ, Herpes zoster; ICBH, iliac crest bone harvest; IFG, impaired fasting glucose; IGT, 
impaired glucose tolerance; KP, knee pain; LANSS, Leeds Assessment of Neuropathic Symptoms and Signs; LS, Lhermitte’s phenomenon; MCS, mental component 
summary; MDNS, Michigan Diabetic Neuropathy Score; MER, Middle East Region; MI, myocardial infarction; MNSI, Michigan Neuropathy Screening Instrument; 
MOS-SS, Medical Outcomes Study Sleep Scale; MS, multiple sclerosis; NDS, neuropathy disability score; NeuP, neuropathic pain; NGT, normal glucose tolerance; 
NKP, neuropathic knee pain; NociP, nociceptive pain; NSS, neuropathy symptom score; OA, osteoarthritis; OS, optic neuritis; PAD, peripheral arterial disease; PCS, 
pain catastrophizing scale; pDPN, painful diabetic peripheral neuropathy; PHN, post-herpetic neuralgia; RA, rheumatoid arthritis; SF-12/36, 12/36-item Short Form 
Health Survey; T1D, type 1 diabetes; T2D, type 2 diabetes; TJR, total joint replacement; TN, trigeminal neuralgia; UK, UAE, United Arab Emirates; United Kingdom; 
USA, United States of America; VL, viral load; ZBPI, Zoster Brief Pain Inventory. 
 


































































aversus <50 years as reference group 
bversus Egypt as reference group 
cHazard ratio 
dOdds ratios relate to the definite NeuP group with No NeuP as the reference 






































































- Painful diabetic neuropathy
- Postherpetic neuralgia
- Neuropathic knee pain

























- Painful HIV-sensory neuropathy
- Neuropathic pain post-TJR
Neurotransmission






(TF, CP, TFRC, ACO1, FXN, 
B2M, BMP6, SLC11A2)
Immune response
(HLA , IL6, TNFA, GFRA2)
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